LaVoieHealthScience Blog

O’Dwyer’s PR News: “The Biopharma Communications Balancing Act”

The Biopharma Communications Balancing Act

LaVoieHealthScience President and CEO, Donna LaVoie, contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations. Donna discusses what makes strategic communications and investor relations in biotech different from other industries. The communications function is often reliant on the entire strategic leadership team in a startup biotech. From her experience, Donna explains how nuances in biotech communications require a unique skillset to articulate a scientific and clinical/commercial story while balancing important strategic imperatives like time sensitive information and regulatory processes.

Read the full article on the O’Dwyer’s PR News website.

LaVoieHealthScience offers integrated communications in life sciences, with specializations in strategy consultinginvestor relations and corporate communications, and public relations and marketing.

Featured Event

No Events

Recent Blog Posts

Managing Turbulent Times and the Integrated Communication Model

An Interview with Gemma Bakx, head of Investor Relations and ESG at LaVoieHealthScience by Paul Sagan, VP, Investor Relations and Corporate Communications PS: What led to your investor relations role at LHS? GB: Donna Lavoie founded her integrated communications...

5 Tips for 2022 Hybrid Conferences

As we continue with hybrid conferences in 2022, here are some tips to help you navigate the digital format and reach your target stakeholders at this year’s hybrid conferences. Take advantage of one-on-one partnering systems offered by the conference to get a head...